Status:
COMPLETED
The Potential Therapeutic Role of Hydroxyethyl Starch and Hydrocortisone in Acute Aluminum Phosphide Poisoning
Lead Sponsor:
Tanta University
Conditions:
Potential Therapeutic Role
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Aluminum phosphide (ALP) is a widely used fumigant due to its efficiency as pesticides. It is available as tablets of Celphos, Alphos or Quickphos which are known as rice tablets. Each tablet weights ...
Detailed Description
Aluminum phosphide (ALP) is a widely used fumigant due to its efficiency as pesticides. It is available as tablets of Celphos, Alphos or Quickphos which are known as rice tablets. Each tablet weights ...
Eligibility Criteria
Inclusion
- Patients with severe acute aluminum phosphide poisoning
- systolic blood pressure (SBP) ≤90 mmHg
- PH ≤ 7.2
- HCO3 ≤15 meq/L
- during the first six hours of admission
Exclusion
- Pregnant and lactating women
- Asymptomatic patients with history of acute aluminum phosphide exposure.
- Patients with co-ingestion to other substances in addition to aluminum phosphide.
- Patients with other major medical conditions (e.g. cardiovascular disease, renal or hepatic failure).
- Patients with previous medical intervention (fluid therapy and vasopressors).
Key Trial Info
Start Date :
July 15 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 30 2024
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT04465539
Start Date
July 15 2020
End Date
March 30 2024
Last Update
May 1 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Tarek Abdel Hay
Tanta, El Gharbyia, Egypt, 31527